Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: A meta-analysis [3]

Cancer

Volumn 109, Issue 2, 2007, Pages 343-

  Bartolozzi, Benedetta ^a   Bosi, Alberto ^a   Orsi, Cecilia ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; HUMAN; KAPLAN MEIER METHOD; LETTER; LEUKEMIA REMISSION; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; META-ANALYSIS; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33846231374     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22406     Document Type: Letter

References (8)

1. Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a meta-analysis. Cancer. 2006; 106:2657-2663.
2. Orsi C. Outcomes in acute lymphoblastic leukaemia in first complete remission treated with allogeneic transplantation. 35th ESCP Symposium, Vienna, Austria, October 18-21, 2006. Abstract PEC-295.
3. Hunault M, Harousscau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104:3028-37.
4. Labar B, Suciu S, Zittoun R, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients ≤50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica. 2004;89:809-817.
5. Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica. 2005;90:1346-1356.
6. Thomas X, Boiron JM, Huguet F, Dombret H, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075-4086.
7. Messori A, Bosi A, Bacci S, et al. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Bone Marrow Transplant. 1999;23:489-495.
8. Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000;18:64-71.